A new approach to drug design can deliver medicine directly to the gut in mice at significantly lower doses than current inflammatory bowel disease treatments. The proof-of-concept study introduced a ...

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...

A man spent 18 years injecting himself with venom, almost dying more than once – and now his blood is behind a new snakebite treatment.

A recent study marks the first reported instance of generative AI designing synthetic molecules that can successfully control gene expression in healthy mammalian cells. As a proof-of-concept, the ...

The collaboration brings together OmniAb's suite of transgenic antibody discovery solutions with VERAXA's proprietary antibody drug conjugate ("ADC”) linker ... financial or operating performance. For ...

The collaboration brings together OmniAb’s suite of transgenic antibody discovery solutions with VERAXA’s proprietary antibody drug conjugate (“ADC”) linker technology and conjugation ...

The collaboration brings together OmniAb's suite of transgenic antibody discovery solutions with VERAXA's proprietary antibody drug conjugate ... performance. For example, statements regarding ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Eric Topol, Executive Vice President of Scripps Research, on his new ...

This manuscript characterizes a mutated clone of RNA polymerase I in yeast, referred to as SuperPol, to understand the mechanisms of RNA polymerase I elongation and termination. The authors present ...

The collaboration brings together OmniAb's suite of transgenic antibody discovery solutions with VERAXA's proprietary antibody drug conjugate ... performance. For example, statements regarding ...